A study to assess the relationship between Health Technology Assessment recommendations and market penetration of the two new FDC triple therapies: glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow) and umeclidinium/vilanterol/fluticasone furoate (Trelegy Ellipta)
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary) ; Fluticasone furoate/umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 27 Nov 2020 New trial record
- 19 Nov 2020 Results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research